DGAP-News: Epigenomics AG / Key word(s): Miscellaneous/Scientific publication24.04.2020 / 07:33 The issuer is solely responsible for the content of this announcement. Epigenomics AG: Epi proColon included in 2020 National Comprehensive Cancer Network Colorectal Cancer Screening Guidelines Berlin (Germany), April 24, 2020 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) announced that Epi proColon, the […]
Author: mark
24. April 2020
Epigenomics AG: Epi proColon included in 2020 National Comprehensive Cancer Network Colorectal Cancer Screening Guidelines
Read more
14. April 2020
Epigenomics AG implements comprehensive measures to reduce costs during the COVID-19 pandemic crisis
DGAP-News: Epigenomics AG / Key word(s): Miscellaneous14.04.2020 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG implements comprehensive measures to reduce costs during the COVID-19 pandemic crisis Berlin (Germany), April 14, 2020 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) has initiated comprehensive measures to reduce costs in […]
17. March 2020
Epigenomics Announces Postponement of Annual General Meeting due to Coronavirus and Preliminary 2019 Flash Financial Results
DGAP-News: Epigenomics AG / Key word(s): AGM/EGM/Preliminary Results17.03.2020 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics Announces Postponement of Annual General Meeting due to Coronavirus and Preliminary 2019 Flash Financial Results Berlin (Germany), March 17, 2020 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), today announced the postponement […]
02. March 2020
Centers for Medicare & Medicaid Services open NCD review process for Epi Pro Colon
DGAP-News: Epigenomics AG / Key word(s): Miscellaneous02.03.2020 / 08:00 The issuer is solely responsible for the content of this announcement. Centers for Medicare & Medicaid Services open NCD review process for Epi Pro Colon Opening of review process guarantees reimbursement decision within next nine months Results of microsimulation model published in November 2019 show competitiveness […]
02. December 2019
Epigenomics AG: Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer
DGAP-News: Epigenomics AG / Key word(s): Study results/Study02.12.2019 / 11:37 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports on New Micro-Simulation Study Results Published in Cancer Medicine Indicating That Epi proColon Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer Adherence rates and screening intervals recognized as […]
29. November 2019
Epigenomics AG: New Micro-Simulation Study in Cancer Medicine Finds Epi proColon(R) Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer
DGAP-News: Epigenomics AG / Key word(s): Study results/Study29.11.2019 / 15:00 The issuer is solely responsible for the content of this announcement. New Micro-Simulation Study in Cancer Medicine Finds Epi proColon(R) Provides Clinically Meaningful Reductions in Incidence and Mortality of Colorectal Cancer Adherence rates and screening intervals recognized as decisive elements of successful screening strategies Berlin […]